Dr. Hammers on Challenges With CAR T-Cell Therapy in RCC

Video

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with CAR T-cell therapy in renal cell carcinoma (RCC).

The introduction of CAR T cells has been practice changing in hematologic malignancies. More success has been seen in leukemia compared with solid tumors like RCC, says Hammers. In leukemia, CAR T-cell therapy typically depletes B cells, but a similar antigen target is not as easy to find in solid tumors. Approaches that increase the specificity of tumor cells and the resistance to the tumor microenvironment may be the key to utilizing CAR T cells more effectively in solid tumors.

Hammers is hopeful that present developments in other diseases will shed light on kidney cancer treatment in the near future.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.